p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: Further evidence for the pathogenesis of the basal phenotype of breast cancer

Histopathology

Volumn 47, Issue 5, 2005, Pages 458-466

  Ribeiro Silva, Alfredo ^a   Ramalho, L N Z ^a   Garcia, S B ^a   Brandao D F ^a   Chahud, F ^a   Zucoloto, S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Basal phenotype; BRCA1; Breast; Carcinoma; Cytokeratin 5; Cytokeratins 8 18; p63

Indexed keywords

BRCA1 PROTEIN; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN ANTIBODY; PROTEIN P53; PROTEIN P63;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATOR GENE; STEM CELL;

ADULT; AGED; BRCA1 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA-BINDING PROTEINS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MIDDLE AGED; PHOSPHOPROTEINS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 27744489092     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02249.x     Document Type: Article

References (36)

1. Bocker W, Moll R, Poremba C et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab. Invest. 2002; 82; 737-746.
2. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406; 747-752.
3. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001; 98; 10869-10874.
4. Abd El-Rehim DM, Pinder SE, Paish CE et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 2004; 203; 661-671.
5. Foulkes WD, Brunet JS, Stefansson IM et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/ glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004; 64; 830-835.
6. Westfall MD, Pietenpol JA. p63: Molecular complexity in development and cancer. Carcinogenesis 2004; 25; 857-864.
7. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br. J. Cancer 1957; 11; 359-377.
8. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 1991; 19; 403-410.
9. Fitzgibbons PL, Page DL, Weaver D et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 2000; 124; 966-978.
10. Woelfle U, Sauter G, Santjer S, Brakenhoff R, Pantel K. Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin. Cancer Res. 2004; 10; 2670-2674.
11. Nieto A, Perez-Alenza MD, Del Castillo N, Tabanera E, Castano M, Pena L. BRCA1 expression in canine mammary dysplasias and tumours: relationship with prognostic variables. J. Comp. Pathol. 2003; 128; 260-268.
12. Ribeiro-Silva A, Ramalho LNZ, Garcia SB, Zucoloto S. The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch. Pathol. Lab. Med. 2003; 127; 336-340.
13. Milde-Langosch K, Bamberger AM, Methner C, Rieck G, Loning T. Expression of cell cycle-regulatory proteins rb, p16/MTS1, p27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members. Int. J. Cancer 2000; 87; 468-472.
14. Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am. J. Clin. Pathol. 2002; 118; 408-417.
15. Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL. Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res. 2003; 5; R242-249.
16. Osada M, Ohba M, Kawahara C et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 1998; 4; 839-843.
17. Trink B, Okami K, Wu L, Sriuranpong V, Jen J, Sidransky D. A new human p53 homologue. Nat. Med. 1998; 4; 747-748.
18. Yang A, Kaghad M, Wang Y et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 1998; 2; 305-316.
19. Maisse C, Guerrieri P, Melino G. p73 and p63 protein stability: the way to regulate function? Biochem. Pharmacol. 2003; 66; 1555-1561.
20. Signoretti S, Waltregny D, Dilks J et al p63 is a prostate basal cell marker and is required for prostate development. Am. J. Pathol. 2000; 157; 1769-1775.
21. Di Como CJ, Urist MJ, Babayan I et al. p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 2002; 8; 494-501.
22. Barbareschi M, Pecciarini L, Cangi MG et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am. J. Surg. Pathol. 2001; 25; 1054-1060.
23. Reis-Filho JS, Schmitt FC. Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv. Anat. Pathol. 2002; 9; 280-289.
24. Wang X, Mori I, Tang W et al. p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 2002; 9; 216-219.
25. Batistatou A, Stefanou D, Arkoumani E, Agnantis NJ. The usefulness of p63 as a marker of breast myoepithelial cells. In Vivo 2003; 17; 573-576.
26. Reis-Filho JS, Milanezi F, Amendoeira I, Albergaria A, Schmitt FC. Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast: an analysis of 82 samples. Cancer 2003; 99; 172-179.
27. Ribeiro-Silva A, Ramalho LNZ, Garcia SB, Zucoloto S. Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast? Pathol. Oncol. Res. 2003; 9; 20-23.
28. Stefanou D, Batistatou A, Nonni A, Arkoumani E, Agnantis NJ. p63 expression in benign and malignant breast lesions. Histol. Histopathol. 2004; 19; 465-471.
29. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003; 443; 122-132.
30. Ellis IO, Schnitt SJ, Sastre-Garau X et al. Invasive breast carcinoma. In Tavassoli FA, Devilee P eds. World Health Organization classification of tumours: tumours of the breast and female genital organs. Lyon: IARC Press 2003; 13-59.
31. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch. 1998; 433; 119-129.
32. Korsching E, Packeisen J, Agelopoulos K et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab. Invest. 2002; 82; 1525-1533.
33. van de Rijn M, Perou CM, Tibshirani R et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol 2002; 161; 1991-1996.
34. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 5367-5374.
35. Foulkes WD. BRCA1 functions as a breast stem cell regulator. J. Med, Genet. 2004; 41; 1-5.
36. Au NH, Gown AM, Cheang M et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl. Immunohistochem. Mol. Morph. 2004; 12; 240-247.